Results 151 to 160 of about 1,862 (162)
Some of the next articles are maybe not open access.
The Role of Phenoconversion in the Pharmacogenetics of Psychiatric Medication
Pharmacogenomics, 2023Martina Hahn, Sibylle C Roll
openaire +2 more sources
Annals of Neurology, 2018
ObjectiveTo evaluate neurofilament light (NfL) as a biomarker of the presymptomatic phase of amyotrophic lateral sclerosis (ALS).MethodsThe study population includes 84 individuals at risk for developing ALS, 34 controls, 17 ALS patients, and 10 phenoconverters (at‐risk individuals observed both before and after the emergence of clinically manifest ...
Benatar, M +4 more
openaire +3 more sources
ObjectiveTo evaluate neurofilament light (NfL) as a biomarker of the presymptomatic phase of amyotrophic lateral sclerosis (ALS).MethodsThe study population includes 84 individuals at risk for developing ALS, 34 controls, 17 ALS patients, and 10 phenoconverters (at‐risk individuals observed both before and after the emergence of clinically manifest ...
Benatar, M +4 more
openaire +3 more sources
The Importance of Phenoconversion when using the CYP2D6 Genotype in Clinical Practice
Pharmacogenomics, 2022Emily Cicali, Kristin Weitzel
exaly
Predicting Phenoconversion in Pure Autonomic Failure (4258)
Neurology, 2020Elizabeth Coon +6 more
openaire +1 more source
PHAROS: Phenoconversion to Manifest Huntington Disease
Archives of Neurology, 2001openaire +1 more source